Hi, I'm Hannah and welcome to the A16Z podcast. We've been hearing hype about the possibilities

of genomics for decades now since the human genome project first began. So where are we today?

In this episode, we look at where genomics actually is right now, what we hoped we would have

by now, what we actually do have and don't, and what we still need to learn,

given that we now know things like your genome changes at an unbelievable rate, from the phenotypic

context needed to make predictions truly accurate, to all the challenges and opportunities for

commercialization. This episode was recorded at our inaugural summit, moderated by A16Z's

Malinka Wallaliate, and joined by Carlos Araya from Jungla, Jeff Kedz from Q, and Gabe Ott from

Frinome. So we're about to get started with a session on genomics. The promise of genomics and where

we are today. And we've got some fantastic entrepreneurs joining us. We've got Jeff, the promise of genomics and where we are today. And we've got some

fantastic entrepreneurs joining us. We've got Jeff, the CEO of Q, Carlos, the CEO of Jongla,

and we've got Gabe, the CEO of Freenome. All right. So when we sequence the first human genome

as part of the human genome project, the promise was that we would cure all disease.

Now, that was 20 years ago.

We certainly haven't lived up to that.

And in fact, it's been a little difficult to see exactly where genomics has had a true application today.

So I'd actually love to get a sense from the crowd.

So I'd love to share a show of hands.

How many of you have had your genome sequenced

and have had that information meaningfully used

to make a change in your health care?

Fairly small fraction, which is exactly what we've been thinking.

...